{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:56:55Z","timestamp":1781308615985,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007472","name":"University of Kentucky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007472","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128410","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:19:55Z","timestamp":1773217195000},"page":"128410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Glycoprotein-specific transcriptional response contributes to differential vaccine protection against lethal Ebola virus infection"],"prefix":"10.1016","volume":"79","author":[{"given":"Sheridan B.","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine C.","family":"Malherbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan G.","family":"Napier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Marzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilhem","family":"Messaoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2026.128410_bb0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-020-0147-3","article-title":"Ebola virus disease","volume":"6","author":"Jacob","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.vaccine.2026.128410_bb0010","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-pathol-052016-100506","article-title":"The pathogenesis of Ebola virus disease","volume":"12","author":"Baseler","year":"2017","journal-title":"Annu Rev Pathol"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2026.128410_bb0015","doi-asserted-by":"crossref","first-page":"S810","DOI":"10.1093\/infdis\/jir299","article-title":"Basic clinical and laboratory features of filoviral hemorrhagic fever","volume":"204","author":"Kortepeter","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128410_bb0020","author":"Centers for Disease Control and Prevention"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2026.128410_bb0025","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1086\/514286","article-title":"Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: risk factors for patients without a reported exposure","volume":"179","author":"Roels","year":"1999","journal-title":"J Infect Dis"},{"issue":"15","key":"10.1016\/j.vaccine.2026.128410_bb0030","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMoa1404505","article-title":"Emergence of Zaire Ebola virus disease in Guinea","volume":"371","author":"Baize","year":"2014","journal-title":"N Engl J Med"},{"issue":"Suppl. 7","key":"10.1016\/j.vaccine.2026.128410_bb0035","article-title":"The multiple origins of Ebola disease outbreaks","volume":"228","author":"Judson","year":"2023","journal-title":"J Infect Dis"},{"issue":"7877","key":"10.1016\/j.vaccine.2026.128410_bb0040","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41586-021-03901-9","article-title":"Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks","volume":"597","author":"Keita","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128410_bb0045","first-page":"171","article-title":"Nonhuman primate models of Ebola virus disease","volume":"411","author":"Bennett","year":"2017","journal-title":"Curr Top Microbiol Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128410_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms8101473","article-title":"To B or not to B: mechanisms of protection conferred by rVSV-EBOV-GP and the roles of innate and adaptive immunity","volume":"8","author":"Pinski","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2026.128410_bb0055","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1093\/infdis\/jiv284","article-title":"Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection","volume":"212 Suppl 2(Suppl 2)","author":"Geisbert","year":"2015","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128410_bb0060","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6249","key":"10.1016\/j.vaccine.2026.128410_bb0065","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.aab3920","article-title":"EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014\/15 Ebola virus outbreak strain","volume":"349","author":"Marzi","year":"2015","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128410_bb0070","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00597-19","article-title":"Antiviral innate responses induced by VSV-EBOV vaccination contribute to rapid protection","volume":"10","author":"Menicucci","year":"2019","journal-title":"mBio"},{"issue":"10068","key":"10.1016\/j.vaccine.2026.128410_bb0075","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola ca Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.vaccine.2026.128410_bb0080","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa1904387","article-title":"Ebola outbreak response in the DRC with rVSV-ZEBOV-GP ring vaccination","volume":"391","author":"Muyembe","year":"2024","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.vaccine.2026.128410_bb0085","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.vaccine.2026.128410_bb0090","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.170074","article-title":"Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial","volume":"189","author":"ElSherif","year":"2017","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2026.128410_bb0095","author":"U.S. Food & Drug Administration"},{"key":"10.1016\/j.vaccine.2026.128410_bb0100","author":"Merck. U.S"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128410_bb0105","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1093\/infdis\/jix189","article-title":"Six-month safety data of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults","volume":"215","author":"Halperin","year":"2017","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128410_bb0110","doi-asserted-by":"crossref","first-page":"98","DOI":"10.15585\/mmwr.su6503a14","article-title":"Implementing an Ebola vaccine study - Sierra Leone","volume":"65","author":"Widdowson","year":"2016","journal-title":"MMWR Suppl"},{"key":"10.1016\/j.vaccine.2026.128410_bb0115","series-title":"Interim recommendations on vaccination against Ebola virus disease (EVD)","article-title":"strategic advisory Group of Experts (SAGE) on immunization","author":"World Health Organization\u2019\u2019s","year":"2019"},{"key":"10.1016\/j.vaccine.2026.128410_bb0120","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ebiom.2019.09.055","article-title":"Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge","volume":"49","author":"Marzi","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2026.128410_bb0125","first-page":"1","article-title":"VSV-EBOV induces temporal and dose-dependent transcriptional responses in non-human primates","author":"Pinski","year":"2021","journal-title":"Front Virology"},{"key":"10.1016\/j.vaccine.2026.128410_bb0130","article-title":"Low-dose VSV-EBOV vaccination provides rapid protection from lethal Ebola virus challenge","author":"Marzi","year":"2026","journal-title":"bioRxiv"},{"key":"10.1016\/j.vaccine.2026.128410_bb0135","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.3389\/fimmu.2018.03071","article-title":"Protection against Marburg virus using a recombinant VSV-vaccine depends on T and B cell activation","volume":"9","author":"Marzi","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128410_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.774026","article-title":"Single dose of a VSV-based vaccine rapidly protects macaques from Marburg virus disease","volume":"12","author":"Marzi","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128410_bb0145","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.vaccine.2026.128410_bb0150","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/1471-2105-7-191","article-title":"STEM: a tool for the analysis of short time series gene expression data","volume":"7","author":"Ernst","year":"2006","journal-title":"BMC Bioinformatics"},{"issue":"18","key":"10.1016\/j.vaccine.2026.128410_bb0155","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1093\/bioinformatics\/btu333","article-title":"Next maSigPro: updating maSigPro bioconductor package for RNA-seq time series","volume":"30","author":"Nueda","year":"2014","journal-title":"Bioinformatics"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128410_bb0160","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128410_bb0165","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128410_bb0170","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.cell.2020.10.002","article-title":"Single-cell profiling of Ebola virus disease in vivo reveals viral and host dynamics","volume":"183","author":"Kotliar","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2026.128410_bb0175","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3389\/fmicb.2017.01571","article-title":"Ebola virus glycoprotein induces an innate immune response in vivo via TLR4","volume":"8","author":"Lai","year":"2017","journal-title":"Front Microbiol"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128410_bb0180","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.3201\/eid2110.150259","article-title":"Delayed disease progression in Cynomolgus macaques infected with Ebola virus Makona strain","volume":"21","author":"Marzi","year":"2015","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128410_bb0185","doi-asserted-by":"crossref","first-page":"9730","DOI":"10.1038\/s41598-017-09963-y","article-title":"Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants","volume":"7","author":"Versteeg","year":"2017","journal-title":"Sci Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:48:14Z","timestamp":1781308094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26002185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":37,"alternative-id":["S0264410X26002185"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128410","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glycoprotein-specific transcriptional response contributes to differential vaccine protection against lethal Ebola virus infection","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128410","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128410"}}